spacer
spacer
Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Transferase PDB id
1tn7
Jmol
Contents
Protein chains
323 a.a. *
407 a.a. *
Ligands
THR-LYS-CYS-VAL-
ILE-PHE
ACY ×2
FII
Metals
_ZN
Waters ×357
* Residue conservation analysis
PDB id:
1tn7
Name: Transferase
Title: Protein farnesyltransferase complexed with a tc21 peptide substrate and a fpp analog at 2.3a resolution
Structure: Protein farnesyltransferase alpha subunit. Chain: a. Synonym: caax farnesyltransferase alpha subunit, ftase- alpha. Engineered: yes. Protein farnesyltransferase beta subunit. Chain: b. Synonym: caax farnesyltransferase beta subunit, ftase-beta. Engineered: yes.
Source: Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: fnta. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: fntb. Synthetic: yes. Other_details: the fusion protein was chemically
Biol. unit: Trimer (from PQS)
Resolution:
2.30Å     R-factor:   0.180     R-free:   0.207
Authors: T.S.Reid,K.L.Terry,P.J.Casey,L.S.Beese
Key ref:
T.S.Reid et al. (2004). Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol, 343, 417-433. PubMed id: 15451670 DOI: 10.1016/j.jmb.2004.08.056
Date:
11-Jun-04     Release date:   02-Nov-04    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
Q04631  (FNTA_RAT) -  Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha
Seq:
Struc:
377 a.a.
323 a.a.
Protein chain
Pfam   ArchSchema ?
Q02293  (FNTB_RAT) -  Protein farnesyltransferase subunit beta
Seq:
Struc:
437 a.a.
407 a.a.
Key:    PfamA domain  PfamB domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class 1: Chains A, B: E.C.2.5.1.58  - Protein farnesyltransferase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
Farnesyl diphosphate
Bound ligand (Het Group name = FII)
matches with 50.00% similarity
+ protein-cysteine
= S-farnesyl protein
+ diphosphate
      Cofactor: Magnesium; Zinc
   Enzyme class 2: Chain A: E.C.2.5.1.59  - Protein geranylgeranyltransferase type I.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Geranylgeranyl diphosphate + protein-cysteine = S-geranylgeranyl- protein + diphosphate
Geranylgeranyl diphosphate
Bound ligand (Het Group name = FII)
matches with 43.00% similarity
+ protein-cysteine
= S-geranylgeranyl- protein
+ diphosphate
      Cofactor: Zinc
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     protein complex   4 terms 
  Biological process     response to inorganic substance   15 terms 
  Biochemical function     catalytic activity     14 terms  

 

 
    reference    
 
 
DOI no: 10.1016/j.jmb.2004.08.056 J Mol Biol 343:417-433 (2004)
PubMed id: 15451670  
 
 
Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
T.S.Reid, K.L.Terry, P.J.Casey, L.S.Beese.
 
  ABSTRACT  
 
Post-translational modifications are essential for the proper function of many proteins in the cell. The attachment of an isoprenoid lipid (a process termed prenylation) by protein farnesyltransferase (FTase) or geranylgeranyltransferase type I (GGTase-I) is essential for the function of many signal transduction proteins involved in growth, differentiation, and oncogenesis. FTase and GGTase-I (also called the CaaX prenyltransferases) recognize protein substrates with a C-terminal tetrapeptide recognition motif called the Ca1a2X box. These enzymes possess distinct but overlapping protein substrate specificity that is determined primarily by the sequence identity of the Ca1a2X motif. To determine how the identity of the Ca1a2X motif residues and sequence upstream of this motif affect substrate binding, we have solved crystal structures of FTase and GGTase-I complexed with a total of eight cognate and cross-reactive substrate peptides, including those derived from the C termini of the oncoproteins K-Ras4B, H-Ras and TC21. These structures suggest that all peptide substrates adopt a common binding mode in the FTase and GGTase-I active site. Unexpectedly, while the X residue of the Ca1a2X motif binds in the same location for all GGTase-I substrates, the X residue of FTase substrates can bind in one of two different sites. Together, these structures outline a series of rules that govern substrate peptide selectivity; these rules were utilized to classify known protein substrates of CaaX prenyltransferases and to generate a list of hypothetical substrates within the human genome.
 
  Selected figure(s)  
 
Figure 1.
Figure 1. Chemical structures of isoprenoid diphosphates and non-hydrolyzable analogs.
Figure 4.
Figure 4. Comparison of the a[2] binding site in FTase and GGTase-I. Superposition of FTase and GGTase-I shows residues that interact with the a[2] residue of the Ca[1]a[2]X motif. Regions of the FTase ternary complex forming the a[2] binding site (enzyme residues Trp102b, Trp106b and Tyr361b and isoprene 3) are colored red. Corresponding regions of the GGTase-I ternary complex (enzyme residues Thr49b, Phe53b and Leu321b, isoprenes 3 and 4, and substrate peptide X residue) are colored blue. Portions of the FPP and GGPP analogs (gray) and of the CVIM (pink) and CVIL (light blue) peptides not forming the a[2] site are shown.
 
  The above figures are reprinted by permission from Elsevier: J Mol Biol (2004, 343, 417-433) copyright 2004.  
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21266773 M.R.Philips (2011).
The perplexing case of the geranylgeranyl transferase-deficient mouse.
  J Clin Invest, 121, 510-513.  
20180535 A.J.DeGraw, M.J.Keiser, J.D.Ochocki, B.K.Shoichet, and M.D.Distefano (2010).
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
  J Med Chem, 53, 2464-2471.  
20005705 A.J.Krzysiak, A.V.Aditya, J.L.Hougland, C.A.Fierke, and R.A.Gibbs (2010).
Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates.
  Bioorg Med Chem Lett, 20, 767-770.  
20421363 B.S.Davies, R.H.Barnes, Y.Tu, S.Ren, D.A.Andres, H.P.Spielmann, J.Lammerding, Y.Wang, S.G.Young, and L.G.Fong (2010).
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
  Hum Mol Genet, 19, 2682-2694.  
19878682 J.L.Hougland, K.A.Hicks, H.L.Hartman, R.A.Kelly, T.J.Watt, and C.A.Fierke (2010).
Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.
  J Mol Biol, 395, 176-190.  
20348589 J.M.Fres, S.Müller, and G.J.Praefcke (2010).
Purification of the CaaX-modified, dynamin-related large GTPase hGBP1 by coexpression with farnesyltransferase.
  J Lipid Res, 51, 2454-2459.  
20106865 R.Lee, S.Y.Chang, H.Trinh, Y.Tu, A.C.White, B.S.Davies, M.O.Bergo, L.G.Fong, W.E.Lowry, and S.G.Young (2010).
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
  Hum Mol Genet, 19, 1603-1617.  
20432425 U.T.Nguyen, R.S.Goody, and K.Alexandrov (2010).
Understanding and exploiting protein prenyltransferases.
  Chembiochem, 11, 1194-1201.  
20726853 Y.S.Oh, D.G.Kim, G.Kim, E.C.Choi, B.K.Kennedy, Y.Suh, B.J.Park, and S.Kim (2010).
Downregulation of lamin A by tumor suppressor AIMP3/p18 leads to a progeroid phenotype in mice.
  Aging Cell, 9, 810-822.  
19692568 F.Calvo, and P.Crespo (2009).
Structural and spatial determinants regulating TC21 activation by RasGRF family nucleotide exchange factors.
  Mol Biol Cell, 20, 4289-4302.  
19320430 J.L.Donelson, H.B.Hodges-Loaiza, B.S.Henriksen, C.A.Hrycyna, and R.A.Gibbs (2009).
Solid-phase synthesis of prenylcysteine analogs.
  J Org Chem, 74, 2975-2981.  
19199818 J.L.Hougland, C.L.Lamphear, S.A.Scott, R.A.Gibbs, and C.A.Fierke (2009).
Context-dependent substrate recognition by protein farnesyltransferase.
  Biochemistry, 48, 1691-1701.  
19784953 L.N.Chan, C.Hart, L.Guo, T.Nyberg, B.S.Davies, L.G.Fong, S.G.Young, B.J.Agnew, and F.Tamanoi (2009).
A novel approach to tag and identify geranylgeranylated proteins.
  Electrophoresis, 30, 3598-3606.  
19246009 M.A.Hast, S.Fletcher, C.G.Cummings, E.E.Pusateri, M.A.Blaskovich, K.Rivas, M.H.Gelb, W.C.Van Voorhis, S.M.Sebti, A.D.Hamilton, and L.S.Beese (2009).
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
  Chem Biol, 16, 181-192.
PDB codes: 3e30 3e32 3e33 3e34 3e37
19451657 R.Rucktäschel, S.Thoms, V.Sidorovitch, A.Halbach, M.Pechlivanis, R.Volkmer, K.Alexandrov, J.Kuhlmann, H.Rottensteiner, and R.Erdmann (2009).
Farnesylation of pex19p is required for its structural integrity and function in peroxisome biogenesis.
  J Biol Chem, 284, 20885-20896.  
19537691 Y.K.Peterson, X.S.Wang, P.J.Casey, and A.Tropsha (2009).
Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation.
  J Med Chem, 52, 4210-4220.  
18844669 A.J.DeGraw, M.A.Hast, J.Xu, D.Mullen, L.S.Beese, G.Barany, and M.D.Distefano (2008).
Caged protein prenyltransferase substrates: tools for understanding protein prenylation.
  Chem Biol Drug Des, 72, 171-181.
PDB code: 3dpy
18176953 J.S.Weiss, H.S.Kruth, H.Kuivaniemi, G.Tromp, J.Karkera, S.Mahurkar, W.Lisch, W.J.Dupps, P.S.White, R.S.Winters, C.Kim, C.J.Rapuano, J.Sutphin, J.Reidy, F.R.Hu, d.a. .W.Lu, N.Ebenezer, and M.L.Nickerson (2008).
Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function.
  Am J Med Genet A, 146, 271-283.  
17996962 K.Yokoyama, J.R.Gillespie, W.C.Van Voorhis, F.S.Buckner, and M.H.Gelb (2008).
Protein geranylgeranyltransferase-I of Trypanosoma cruzi.
  Mol Biochem Parasitol, 157, 32-43.  
18713740 M.A.Hast, and L.S.Beese (2008).
Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate.
  J Biol Chem, 283, 31933-31940.
PDB code: 3dra
18321704 M.Maynor, S.A.Scott, E.L.Rickert, and R.A.Gibbs (2008).
Synthesis and evaluation of 3- and 7-substituted geranylgeranyl pyrophosphate analogs.
  Bioorg Med Chem Lett, 18, 1889-1892.  
18614539 P.J.Roberts, N.Mitin, P.J.Keller, E.J.Chenette, J.P.Madigan, R.O.Currin, A.D.Cox, O.Wilson, P.Kirschmeier, and C.J.Der (2008).
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.
  J Biol Chem, 283, 25150-25163.  
18985644 T.Subramanian, S.Liu, J.M.Troutman, D.A.Andres, and H.P.Spielmann (2008).
Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity.
  Chembiochem, 9, 2872-2882.  
  17530735 A.J.Krzysiak, D.S.Rawat, S.A.Scott, J.E.Pais, M.Handley, M.L.Harrison, C.A.Fierke, and R.A.Gibbs (2007).
Combinatorial modulation of protein prenylation.
  ACS Chem Biol, 2, 385-389.  
17804232 A.J.Krzysiak, S.A.Scott, K.A.Hicks, C.A.Fierke, and R.A.Gibbs (2007).
Evaluation of protein farnesyltransferase substrate specificity using synthetic peptide libraries.
  Bioorg Med Chem Lett, 17, 5548-5551.  
17476360 A.K.Sjogren, K.M.Andersson, M.Liu, B.A.Cutts, C.Karlsson, A.M.Wahlstrom, M.Dalin, C.Weinbaum, P.J.Casey, A.Tarkowski, B.Swolin, S.G.Young, and M.O.Bergo (2007).
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
  J Clin Invest, 117, 1294-1304.  
17932039 A.Shutes, C.Onesto, V.Picard, B.Leblond, F.Schweighoffer, and C.J.Der (2007).
Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
  J Biol Chem, 282, 35666-35678.  
17918965 G.Cui, and K.M.Merz (2007).
Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.
  Biochemistry, 46, 12375-12381.  
17897752 M.Ikeda, and N.Kato (2007).
Modulation of host metabolism as a target of new antivirals.
  Adv Drug Deliv Rev, 59, 1277-1289.  
17476354 M.R.Philips, and A.D.Cox (2007).
Geranylgeranyltransferase I as a target for anti-cancer drugs.
  J Clin Invest, 117, 1223-1225.  
17585331 P.A.Konstantinopoulos, M.V.Karamouzis, and A.G.Papavassiliou (2007).
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
  Nat Rev Drug Discov, 6, 541-555.  
17496923 P.J.Roberts, and C.J.Der (2007).
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
  Oncogene, 26, 3291-3310.  
17439118 S.Lenevich, J.Xu, A.Hosokawa, C.J.Cramer, and M.D.Distefano (2007).
Transition state analysis of model and enzymatic prenylation reactions.
  J Am Chem Soc, 129, 5796-5797.  
17514686 T.Suzuki, M.Ito, T.Ezure, M.Shikata, E.Ando, T.Utsumi, S.Tsunasawa, and O.Nishimura (2007).
Protein prenylation in an insect cell-free protein synthesis system and identification of products by mass spectrometry.
  Proteomics, 7, 1942-1950.  
16732889 B.Couderc, M.Penary, M.Tohfe, A.Pradines, A.Casteignau, D.Berg, and G.Favre (2006).
Reversible inactivation of the transcriptional function of P53 protein by farnesylation.
  BMC Biotechnol, 6, 26.  
16757970 D.Santini, M.Caraglia, B.Vincenzi, I.Holen, S.Scarpa, A.Budillon, and G.Tonini (2006).
Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
  Nat Clin Pract Oncol, 3, 325-338.  
16868926 E.Rung, P.A.Friberg, C.Bergh, and H.Billig (2006).
Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells.
  Mol Reprod Dev, 73, 1277-1283.  
16361710 L.J.Plummer, E.R.Hildebrandt, S.B.Porter, V.A.Rogers, J.McCracken, and W.K.Schmidt (2006).
Mutational analysis of the ras converting enzyme reveals a requirement for glutamate and histidine residues.
  J Biol Chem, 281, 4596-4605.  
16983387 M.H.Gelb, L.Brunsveld, C.A.Hrycyna, S.Michaelis, F.Tamanoi, W.C.Van Voorhis, and H.Waldmann (2006).
Therapeutic intervention based on protein prenylation and associated modifications.
  Nat Chem Biol, 2, 518-528.  
16517596 Y.K.Peterson, P.Kelly, C.A.Weinbaum, and P.J.Casey (2006).
A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
  J Biol Chem, 281, 12445-12450.  
15864282 A.M.Winter-Vann, and P.J.Casey (2005).
Post-prenylation-processing enzymes as new targets in oncogenesis.
  Nat Rev Cancer, 5, 405-412.  
16020528 D.E.Nelson, D.P.Virok, H.Wood, C.Roshick, R.M.Johnson, W.M.Whitmire, D.D.Crane, O.Steele-Mortimer, L.Kari, G.McClarty, and H.D.Caldwell (2005).
Chlamydial IFN-gamma immune evasion is linked to host infection tropism.
  Proc Natl Acad Sci U S A, 102, 10658-10663.  
16191483 N.Ferri, R.Paoletti, and A.Corsini (2005).
Lipid-modified proteins as biomarkers for cardiovascular disease: a review.
  Biomarkers, 10, 219-237.  
15837621 N.Mijimolle, J.Velasco, P.Dubus, C.Guerra, C.A.Weinbaum, P.J.Casey, V.Campuzano, and M.Barbacid (2005).
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.
  Cancer Cell, 7, 313-324.  
15837619 S.M.Sebti (2005).
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
  Cancer Cell, 7, 297-300.  
15960807 S.Maurer-Stroh, and F.Eisenhaber (2005).
Refinement and prediction of protein prenylation motifs.
  Genome Biol, 6, R55.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.